Economic Burden of Osteoporotic Patients with Fracture: Effect of Treatment With or Without Calcium/Vitamin D Supplements

被引:6
作者
Degli Esposti, Luca [1 ]
Saragoni, Stefania [1 ]
Perrone, Valentina [1 ]
Sella, Stefania [2 ,3 ]
Andretta, Margherita [4 ]
Rossini, Maurizio [5 ]
Giannini, Sandro [2 ,3 ]
机构
[1] CliCon Srl, Hlth Econ & Outcomes Res, Via Salara 36, I-48121 Ravenna, Italy
[2] Univ Padua, Dept Med, Clin Med 1, Padua, Italy
[3] Reg Ctr Osteoporosis, Padua, Italy
[4] UOC HTA, Azienda Zero, Padua, Italy
[5] Azienda Osped Univ Integrata Verona & Reg Ctr Ost, Rheumatol Unit, Verona, Italy
关键词
healthcare costs; calcium/vitamin D supplementation; osteoporosis; fracture; hospitalization; VITAMIN-D; FRAGILITY FRACTURES; COST-EFFECTIVENESS; PREVENTION; CALCIUM; DRUGS; WOMEN;
D O I
10.2147/NDS.S234911
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Fractures represent the most important complication of osteoporosis, in terms of loss of independency, chronic pain, increased risk of mortality, but also high healthcare costs. Objective: To assess healthcare costs in an Italian cohort of osteoporotic patients with a fracture with and without specific osteoporosis treatment and supplementation with calcium/vitamin D. Methods: This retrospective observational study used data from administrative databases of five Local Health Units in Italy. Patients >= 50 years of age and hospitalized for vertebral or hip fracture occurring from 01/01/2011 to 31/12/2015 were included. Patients were then classified as "untreated" and "treated" if they had been treated or not with drugs for fracture prevention after the index fracture. We also identified subjects that were only treated with drugs for fracture prevention, "osteoporosis drug only" group, compared to the "osteoporosis drug plus calcium/vitamin D" group, in which calcium and/or vitamin D were also in combination. Healthcare cost analysis included drug expenditure, hospitalization costs (excluding costs related to the hospitalization for the index fracture) and outpatient service costs. Results: Three thousand four hundred and seventy-five patients were included in the present study, most of whom (58.5%) had received specific osteoporosis treatment after index fracture. Among treated patients, the vast majority (83.6%) received supplementation with calcium/vitamin D. Mean annual healthcare cost per patient was (sic)9,289.85 in the untreated group and (sic)4,428.26 for treated subjects (p < 0.001); mean annual healthcare cost for the osteoporosis drug-only group was higher compared to the osteoporosis drug plus calcium/ vitamin D group (sic)5,976.88 vs (sic)4,124.74, respectively, p < 0.001). Hospitalization costs accounted for the majority of total costs in all groups of patients. Conclusion: Healthcare costs in patients with osteoporotic fractures were significantly lower in those receiving osteoporosis treatment compared to untreated patients with even lower costs observed in patients that were also receiving calcium/vitamin D supplements.
引用
收藏
页码:21 / 30
页数:10
相关论文
共 28 条
[1]  
Agenzia Italiana del Farmaco (AIFA), 79 AIFA
[2]  
Agenzia Italiana del Farmaco (AIFA), 2010, Guideline for the Classification and Conduction of the Observational Studies on Medicines Published Online
[3]   Vitamin D Level Between Calcium-Phosphorus Homeostasis and Immune System: New Perspective in Osteoporosis [J].
Bellavia, Daniele ;
Costa, Viviana ;
De Luca, Angela ;
Maglio, Melania ;
Pagani, Stefania ;
Fini, Milena ;
Giavaresi, Gianluca .
CURRENT OSTEOPOROSIS REPORTS, 2024, 22 (06) :599-610
[4]   Vitamin D: Link between Osteoporosis, Obesity, and Diabetes? [J].
Candido, Flavia Galvao ;
Bressan, Josefina .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (04) :6569-6591
[5]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[6]   Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study [J].
Choi, Nam-Kyong ;
Solomon, Daniel H. ;
Tsacogianis, Theodore N. ;
Landon, Joan E. ;
Song, Hong Ji ;
Kim, Seoyoung C. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (03) :611-617
[7]   Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk [J].
Degli Esposti, Luca ;
Girardi, Anna ;
Saragoni, Stefania ;
Sella, Stefania ;
Andretta, Margherita ;
Rossini, Maurizio ;
Giannini, Sandro ;
Vercellone, A. ;
Nava, E. ;
Ferrante, F. ;
Bianchi, C. ;
Crescenzi, S. ;
Venditti, P. F. ;
Folcatrelli, M. ;
Constantini, A. ;
Cattaruzzi, C. .
ENDOCRINE, 2019, 64 (02) :367-377
[8]   Comparing therapies for postmenopausal osteoporosis prevention and treatment [J].
Eichner, SF ;
Lloyd, KB ;
Timpe, EM .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (05) :711-724
[9]  
Esposti LD, 2011, FARMECONOMIA, V12, P99
[10]   Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis [J].
Freemantle, N. ;
Cooper, C. ;
Diez-Perez, A. ;
Gitlin, M. ;
Radcliffe, H. ;
Shepherd, S. ;
Roux, C. .
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) :209-217